Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

Inclusion Criteria: 1. Provision of written informed consent 2. \[MDD stream only\] Diagnosis of major depressive disorder, currently depressed as determined by DSM-IV diagnostic criteria (confirmed using the MINI) 3. \[BD stream only\] Diagnosis of bipolar disorder, type I or type II, currently depressed as determined by DSM-IV diagnostic criteria (confirmed using the MINI) 4. Both females and males, aged 18 to 65 years 5. Inpatient status 6. Female patients of childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test at enrolment and must be taking or willing to take some acceptable form of birth control during the course of the study if they are or plan to be sexually active 7. The ability to understand and comply with the requirements of the study and capable of providing informed consent 8. Suffering from suicidal ideation/attempts as evidenced by a score of \>0 on either of the SSI or CSSRS or both. Exclusion Criteria: 1. Current or past psychotic symptoms 2. Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria 3. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment 4. Any pervasive developmental disorder (according to DSM-IV criteria) 5. Diagnosis of dementia (according to DSM-IV criteria) 6. Known intolerance or hypersensitivity to ketamine or midazolam as judged by the investigator 7. Significant medical condition that would contraindicate the use of ketamine, midazolam or that is untreated and would need urgent attention (as determined by treating physician) 8. Medical conditions that would significantly affect absorption, distribution, metabolism, or excretion of ketamine or midazolam 9. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator 10. Any clinically significant deviation from the reference range in clinical laboratory test results as judged by the investigator 11. Pregnancy (or female of child-bearing age not using adequate contraception) or lactation 12. A positive β-hCG test at enrollment 13. Involvement in the planning and conduct of the study 14. Previous enrollment or randomisation of treatment in the present study 15. Participation in another drug trial within 4 weeks prior enrollment into this study or longer in accordance with local requirements